Metabolic fitness of CAR T cells for cancer therapy Chimeric antigen receptor T cells (CAR-T) are at the forefront of novel immunotherapies against CD19 expressing B cell malignancies. While in some patients CAR-T infusion leads to complete and sustained clearance of the cancer, a significant proportion have primary resistance to treatment or fail to achieve durable clinical responses. Efficacy in solid tumours has not met the success levels seen in B cell CAR-T indications. There is a clear need for better understanding of successes and failures to catalyse optimal CAR-T design. Together with Sophie Papa and Reuben Benjamin we aim to investigate the correlation between the metabolic status of CAR-T and their anti-cancer properties and to elucidate the mechanisms driving these metabolic alterations in order develop strategies to modulate CAR T cell metabolic fitness to improve efficacy and longevity. This project is led by PhD-student Molly George.